Overview

Towards Enhanced Recovery After Cesarean

Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
0
Participant gender:
Female
Summary
One in 300 women will become persistent opioid users after cesarean delivery (1). Cesarean delivery is the most common surgical procedure in the United States, representing 31.9% of the 3,788,235 deliveries in 2018 (2). Patients have to cope with the pain and challenges of post-operative care while adjusting to motherhood and completing activities of daily living. Often when they return home, they are also tasked with other domestic roles which compounds the challenge of this post-operative period. With a potential impact just in the US on 1.2 million mothers each year, optimizing post-operative pain management in order to reduce the risk of persistent opioid use represents an urgent unmet public health goal. To this end, there are national efforts to reduce the cesarean rate and optimize post-cesarean pain management (3,4). The majority of efforts in the last few years have focused on home-going medications and alterations in prescription practices. Recent recommendations from the Enhanced Recovery After Surgery Society indicate that patients should receive multi-modal analgesia on a regular basis, along with early post-delivery mobilization (3). However, the efficacy of scheduled non-steroidal anti-inflammatory medications (NSAID) along with acetaminophen in the immediate post-operative period and after going home have not been systematically studied in the cesarean population. We hypothesize that patients who receive scheduled medications in the post-operative period are less likely to require opioids for pain relief both in the hospital and after they return home.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Oklahoma
Treatments:
Acetaminophen
Ibuprofen
Oxycodone
Criteria
Inclusion Criteria:

- Undergoing repeat cesarean delivery

- ≥37 week gestation

- attended at least 7 prenatal visits

- age ≥18.

Exclusion Criteria:

- Non-English speaking, attended < 7 prenatal visits, fetal anomalies or death,
inability to ambulate, BMI ≥45kg/m2 at delivery due to higher risk of regional
analgesia complications, placental implantation abnormalities, maternal diabetes due
to the risk of wound complications, chorioamnionitis, allergy to study medications,
underlying renal or hepatic impairment, opioid use in the last 3 months, chronic
controlled substance use, chronic pain disorders, history of narcotic addiction,
intraoperative hemorrhage not controlled with medication alone, additional concurrent
surgeries other than sterilization procedures and presence of endometriosis noted at
time of surgery. Patients will be enrolled and randomized to their respective groups
after completion of the surgery, as there may be surgical complications that preclude
their final enrollment as described in the exclusion criteria.